You are here: Home » PTI Stories » National » News
Business Standard

Cipla gets USFDA nod for osteoarthritis of joint pain relief gel

Press Trust of India  |  New Delhi 

Drug today said it has received final approval from the Food and Drug Administration (USFDA) for Sodium Topical Gel, indicated for the relief of the of of joints such as the knees and hands.

Sodium Topical Gel, 1 per cent is a generic therapeutic equivalent to the reference listed drug (RLD), Voltaren Gel, 1 per cent of Consumer Health, in a BSE filing.

Citing IQVIA data, the company said Voltaren Gel and its generic equivalents had US sales of approximately USD 353 million for the 12 month period ending June 2018.

said the product will be available for shipping in the US in the upcoming week.

The company's stock was trading 1.20 per cent lower at Rs 629.45 per scrip on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, August 07 2018. 10:35 IST